Why is Beryl Drugs falling/rising?

As of 11-Sep, Beryl Drugs Ltd is experiencing a decline in its stock price, currently at 23.80, reflecting a decrease of 0.36 or 1.49%. The stock has underperformed its sector by 1.96% today, and its delivery volume has significantly dropped by 51.45% compared to the 5-day average, indicating falling investor participation. Over the past week, the stock has seen a return of -4.76%, while it has performed better over the past month with a return of +29.42%. However, the stock's long-term performance remains concerning, with a year-to-date return of -34.16% and a one-year return of -38.44%. The company's fundamentals are weak, with a low average Return on Capital Employed (ROCE) of 7.27% and a poor EBIT to Interest ratio of 0.86, which raises concerns about its ability to service debt.
In the broader market context, the Sensex has shown a modest gain of 1.03% over the past week, contrasting sharply with Beryl Drugs' negative performance. While the stock is trading at a discount compared to its peers' average historical valuations, the significant drop in profits by 37% over the past year has contributed to the stock's decline. Additionally, the company's flat results in June and weak long-term growth metrics further exacerbate the negative sentiment surrounding the stock. Overall, Beryl Drugs' recent price movement reflects a combination of weak fundamentals, declining investor interest, and underperformance relative to the broader market.